List view / Grid view

Stuart Jamieson (Lonza)

 

article

Rapid method development to overcome challenges of bi-specific antibody purification

27 June 2022 | By ,

The landscape of biopharmaceutical manufacturing is changing, with complex molecules such as bi-specific antibodies (bsAbs) becoming increasingly prevalent. bsAbs are a large, structurally diverse family of molecules designed to recognise two targets and globally there are over 230 in development as promising therapies for cancer and other diseases. While they…